antihemophilic

antihemophilic

 [an″te-, an″ti-he″mo-fil´ik]
1. effective against the bleeding tendency in hemophilia.
2. an agent that has this effect.

an·ti·he·mo·phil·ic

(an'tē-hē-mō-fil'ik)
Correcting or counteracting the hemorrhagic tendency in hemophilia.
Synonym(s): antihaemophilic.
[anti- + hemophilic]
References in periodicals archive ?
Eloctate[R], a recombinant antihemophilic Factor VIII, Fc Fusion Protein, indicated for the treatment of hemophilia A, generated sales of [euro]176 million in the second quarter, up 20.0% on a pro forma basis.
Summary: Fact.MR has announced the addition of the " Cryoprecipitated Antihemophilic Factor Market Forecast, Trend Analysis & Competition Tracking - Global Market insights 2018 to 2028"report to their offering.
The company said Jivi (BAY94-9027, antihemophilic factor [recombinant] PEGylated-aucl) has been approved by the US FDA for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of age or older.
Adynovi is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding, Shire says in a statement.
Food and Drug Administration, FDA Approves Modified Antihemophilic Factor for Hemophilia A, U S Food and Drug Administration, 2016, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472643.htm.
Powell, "Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand's disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor," The Journal of Clinical Investigation, vol.
A and B types are clinically indistinguishable [3] and are caused by deficiencies of the coagulation mechanism factors VIII (or antihemophilic factor) and IX (or plasma thromboplastin component), respectively; C subtype results from a deficiency of factor XI [2, 8].
Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure.
ReFacto AF (moroctocog alfa)/XYNTHA (Antihemophilic Factor (Recombinant)) is a recombinant protein drug for treatment and prevention of bleeding in patients with haemophilia A, a rare, chronic, genetic disorder in which the ability of a person's blood to clot is impaired due to missing or reduced levels of a protein known as factor VIII.
Elocta is also approved in the U.S., Canada, Australia, New Zealand, Japan and other countries where itis known as Eloctate (Antihemophilic Factor (Recombinant), Fc Fusion Protein).